125 related articles for article (PubMed ID: 20550118)
1. Isopropylidene substitution increases activity and selectivity of biphenylmethylene 4-pyridine type CYP17 inhibitors.
Hu Q; Yin L; Jagusch C; Hille UE; Hartmann RW
J Med Chem; 2010 Jul; 53(13):5049-53. PubMed ID: 20550118
[TBL] [Abstract][Full Text] [Related]
2. Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.
Hu Q; Jagusch C; Hille UE; Haupenthal J; Hartmann RW
J Med Chem; 2010 Aug; 53(15):5749-58. PubMed ID: 20684610
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17alpha-hydroxylase-17,20-lyase (CYP17)--part II: Core rigidification and influence of substituents at the methylene bridge.
Hu Q; Negri M; Jahn-Hoffmann K; Zhuang Y; Olgen S; Bartels M; Müller-Vieira U; Lauterbach T; Hartmann RW
Bioorg Med Chem; 2008 Aug; 16(16):7715-27. PubMed ID: 18674917
[TBL] [Abstract][Full Text] [Related]
4. Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modelling of methoxy- and hydroxy-substituted methyleneimidazolyl biphenyls.
Hille UE; Hu Q; Vock C; Negri M; Bartels M; Müller-Vieira U; Lauterbach T; Hartmann RW
Eur J Med Chem; 2009 Jul; 44(7):2765-75. PubMed ID: 19211174
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, biological evaluation, and molecular modeling of abiraterone analogues: novel CYP17 inhibitors for the treatment of prostate cancer.
Pinto-Bazurco Mendieta MA; Negri M; Jagusch C; Müller-Vieira U; Lauterbach T; Hartmann RW
J Med Chem; 2008 Aug; 51(16):5009-18. PubMed ID: 18672868
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel 1,2,3,4-tetrahydrobenzo[4, 5]thieno[2, 3-c]pyridine derivatives as potent and selective CYP17 inhibitors.
Wang M; Fang Y; Gu S; Chen F; Zhu Z; Sun X; Zhu J
Eur J Med Chem; 2017 May; 132():157-172. PubMed ID: 28350999
[TBL] [Abstract][Full Text] [Related]
7. Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors.
Rafferty SW; Eisner JR; Moore WR; Schotzinger RJ; Hoekstra WJ
Bioorg Med Chem Lett; 2014 Jun; 24(11):2444-7. PubMed ID: 24775307
[TBL] [Abstract][Full Text] [Related]
8. CYP17 inhibitors for prostate cancer treatment--an update.
Moreira VM; Salvador JA; Vasaitis TS; Njar VC
Curr Med Chem; 2008; 15(9):868-99. PubMed ID: 18473796
[TBL] [Abstract][Full Text] [Related]
9. CYP17 inhibitors. Annulations of additional rings in methylene imidazole substituted biphenyls: synthesis, biological evaluation and molecular modelling.
Pinto-Bazurco Mendieta MA; Negri M; Hu Q; Hille UE; Jagusch C; Jahn-Hoffmann K; Müller-Vieira U; Schmidt D; Lauterbach T; Hartmann RW
Arch Pharm (Weinheim); 2008 Oct; 341(10):597-609. PubMed ID: 18720339
[TBL] [Abstract][Full Text] [Related]
10. The role of fluorine substitution in biphenyl methylene imidazole-type CYP17 inhibitors for the treatment of prostate carcinoma.
Hu Q; Negri M; Olgen S; Hartmann RW
ChemMedChem; 2010 Jun; 5(6):899-910. PubMed ID: 20437447
[TBL] [Abstract][Full Text] [Related]
11. New benzothieno[2,3-
Khalil NA; Ahmed EM; Zaher AF; Sobh EA; El-Sebaey SA; El-Zoghbi MS
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1839-1859. PubMed ID: 34338119
[TBL] [Abstract][Full Text] [Related]
12. Computational prediction of new CYP17 inhibitors based on pharmacophore modeling, virtual screening and docking approach.
Haidar S; Hartmann RW
Pharmazie; 2017 Sep; 72(9):529-536. PubMed ID: 29441980
[TBL] [Abstract][Full Text] [Related]
13. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
14. Imidazole substituted biphenyls: a new class of highly potent and in vivo active inhibitors of P450 17 as potential therapeutics for treatment of prostate cancer.
Wachall BG; Hector M; Zhuang Y; Hartmann RW
Bioorg Med Chem; 1999 Sep; 7(9):1913-24. PubMed ID: 10530940
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of novel steroidal imidazoles as dual inhibitors of AR/CYP17 for the treatment of prostate cancer.
Hou Q; He C; Lao K; Luo G; You Q; Xiang H
Steroids; 2019 Oct; 150():108384. PubMed ID: 30885648
[TBL] [Abstract][Full Text] [Related]
16. Highly potent and selective nonsteroidal dual inhibitors of CYP17/CYP11B2 for the treatment of prostate cancer to reduce risks of cardiovascular diseases.
Pinto-Bazurco Mendieta MA; Hu Q; Engel M; Hartmann RW
J Med Chem; 2013 Aug; 56(15):6101-7. PubMed ID: 23859149
[TBL] [Abstract][Full Text] [Related]
17. Hits identified in library screening demonstrate selective CYP17A1 lyase inhibition.
Krug SJ; Hu Q; Hartmann RW
J Steroid Biochem Mol Biol; 2013 Mar; 134():75-9. PubMed ID: 23142656
[TBL] [Abstract][Full Text] [Related]
18. CYP17 inhibitors for prostate cancer therapy.
Vasaitis TS; Bruno RD; Njar VC
J Steroid Biochem Mol Biol; 2011 May; 125(1-2):23-31. PubMed ID: 21092758
[TBL] [Abstract][Full Text] [Related]
19. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
Handratta VD; Vasaitis TS; Njar VC; Gediya LK; Kataria R; Chopra P; Newman D; Farquhar R; Guo Z; Qiu Y; Brodie AM
J Med Chem; 2005 Apr; 48(8):2972-84. PubMed ID: 15828836
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of p450 17 as a new strategy for the treatment of prostate cancer.
Leroux F
Curr Med Chem; 2005; 12(14):1623-9. PubMed ID: 16022662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
